Thomas Jefferson University

Jay Schneider

TitleProfessor
InstitutionThomas Jefferson University
DepartmentAnatomy
Address1020 Locust St.
Philadelphia PA 19107
vCardDownload vCard

    Collapse Research 
    Collapse research activities and funding
    R03DE007282     (SCHNEIDER, JAY S)Sep 1, 1985 - Nov 30, 1987
    NIH
    BASAL GANGLIA-TRIGEMINAL INTERACTIONS
    Role: Principal Investigator
    R03MH041645     (SCHNEIDER, JAY S)Aug 1, 1986 - Apr 30, 1988
    NIH
    NEUROPSYCHOLOGICAL STUDIES OF MPTP-INDUCED DOPAMINE
    Role: Principal Investigator
    R01NS023980     (SCHNEIDER, JAY S)Feb 1, 1988 - Jun 30, 2001
    NIH
    NEUROBEHAVIORAL PLASTICITY AFTER DOPAMINE SYSTEM DAMAGE
    Role: Principal Investigator
    R03DE008991     (SCHNEIDER, JAY S)Aug 1, 1988 - Jul 31, 1990
    NIH
    PHARMACOLOGICAL STUDIES OF TRIGEMINAL-BASAL GANGLIA
    Role: Principal Investigator
    R01MH046531     (SCHNEIDER, JAY S)Sep 30, 1991 - Apr 30, 2001
    NIH
    NEUROPSYCHOLOGY OF CATECHOLAMINE DEFICIENCIES
    Role: Principal Investigator
    R01AG010280     (SCHNEIDER, JAY S)Sep 30, 1992 - Jul 31, 1996
    NIH
    DEGENERATION, REPAIR AND AGING IN THE CNS
    Role: Principal Investigator
    R01NS038681     (SCHNEIDER, JAY S)Jun 1, 1999 - May 31, 2010
    NIH
    GM1 Ganglioside Effects on Parkinson's Disease
    Role: Principal Investigator
    R01DA013452     (SCHNEIDER, JAY S)Jul 1, 2000 - Feb 28, 2010
    NIH
    Nicotine and Cognition in Parkinsonism
    Role: Principal Investigator
    U10NS044481     (SCHNEIDER, JAY S)Sep 30, 2002 - Nov 30, 2015
    NIH
    NIH Exploratory Trials in Parkinson's Disease (NET-PD): Clinical Site
    Role: Principal Investigator
    R01ES015295     (SCHNEIDER, JAY S)Dec 1, 2006 - Mar 31, 2020
    NIH
    Environment and Gene Effects on Brain and Behavior
    Role: Principal Investigator
    R01NS055916     (SCHNEIDER, JAY S)Jan 15, 2008 - Dec 31, 2013
    NIH
    Attention and Executive Functioning in Aging and Parkisonism
    Role: Principal Investigator
    R01ES021534     (CORY-SLECHTA, DEBORAH A)Dec 1, 2012 - Oct 31, 2018
    NIH
    CNS Glucocorticoid Epigenetic Changes of Pb Stress Effects
    Role: Co-Principal Investigator
    R21ES024884     (SCHNEIDER, JAY S)Jul 1, 2015 - Oct 1, 2017
    NIH
    Retinal Imaging with Optical Coherence Tomography as a Biomarker for Manganese Neurotoxicity
    Role: Principal Investigator
    R56ES030384     (SCHNEIDER, JAY S)Jun 15, 2019 - Jun 14, 2021
    NIH
    The Role of m6A-RNA Methylation in Memory Formation and Recall and Its Modulation and Influence on Long-Term Outcomes as a Consequence of Early Life Lead Exposure.
    Role: Principal Investigator
    R01ES030742     (SCHNEIDER, JAY S)Aug 14, 2020 - May 31, 2025
    NIH
    Early Life Environment Modifies Behavioral, Epigenetic, and Transcriptional Outcomes from Developmental Lead Exposure
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Schneider JS, Singh G, Williams CK, Singh V. GM1 ganglioside modifies microglial and neuroinflammatory responses to a-synuclein in the rat AAV-A53T a-synuclein model of Parkinson's disease. Mol Cell Neurosci. 2022 May; 120:103729. PMID: 35447351.
      Citations:    
    2. Schneider JS, Kortagere S. Current concepts in treating mild cognitive impairment in Parkinson's disease. Neuropharmacology. 2022 02 01; 203:108880. PMID: 34774549.
      Citations:    
    3. Schneider JS, Marshall CA, Keibel L, Snyder NW, Hill MP, Brotchie JM, Johnston TH, Waterhouse BD, Kortagere S. A novel dopamine D3R agonist SK609 with norepinephrine transporter inhibition promotes improvement in cognitive task performance in rodent and non-human primate models of Parkinson's disease. Exp Neurol. 2021 Jan; 335:113514. PMID: 33141071.
      Citations:    
    4. Schneider JS, Aras R, Williams CK, Koprich JB, Brotchie JM, Singh V. GM1 Ganglioside Modifies a-Synuclein Toxicity and is Neuroprotective in a Rat a-Synuclein Model of Parkinson's Disease. Sci Rep. 2019 Jun 10; 9(1):8362. PMID: 31182727.
      Citations:    
    5. Neuwirth LS, Masood S, Anderson DW, Schneider JS. The Attention Set-Shifting Test is Sensitive for Revealing Sex-based Impairments in Executive Functions Following Developmental Lead Exposure in Rats. Behav Brain Res. 2019 Mar 13. PMID: 30878351.
      Citations:    
    6. Guilarte TR, Yeh CL, McGlothan JL, Perez J, Finley P, Zhou Y, Wong DF, Dydak U, Schneider JS. PET imaging of dopamine release in the frontal cortex of manganese-exposed non-human primates. J Neurochem. 2019 Feb 05. PMID: 30720866.
      Citations:    
    7. Verma M, Schneider JS. siRNA-mediated knockdown of B3GALT4 decreases GM1 ganglioside expression and enhances vulnerability for neurodegeneration. Mol Cell Neurosci. 2019 Jan 03; 95:25-30. PMID: 30611881.
      Citations:    
    8. Sobolewski M, Singh G, Schneider JS, Cory-Slechta DA. Different Behavioral Experiences Produce Distinctive Parallel Changes in, and Correlate With, Frontal Cortex and Hippocampal Global Post-translational Histone Levels. Front Integr Neurosci. 2018; 12:29. PMID: 30072878.
      Citations:    
    9. Schneider JS. Altered expression of genes involved in ganglioside biosynthesis in substantia nigra neurons in Parkinson's disease. PLoS One. 2018; 13(6):e0199189. PMID: 29902255.
      Citations:    
    10. Castonguay D, Dufort-Gervais J, Ménard C, Chatterjee M, Quirion R, Bontempi B, Schneider JS, Arnsten AFT, Nairn AC, Norris CM, Ferland G, Bézard E, Gaudreau P, Lombroso PJ, Brouillette J. The Tyrosine Phosphatase STEP Is Involved in Age-Related Memory Decline. Curr Biol. 2018 04 02; 28(7):1079-1089.e4. PMID: 29576474.
      Citations:    
    11. Singh G, Singh V, Sobolewski M, Cory-Slechta DA, Schneider JS. Sex-Dependent Effects of Developmental Lead Exposure on the Brain. Front Genet. 2018; 9:89. PMID: 29662502.
      Citations:    
    12. Sobolewski M, Varma G, Adams B, Anderson DW, Schneider JS, Cory-Slechta DA. Developmental Lead Exposure and Prenatal Stress Result in Sex-Specific Reprograming of Adult Stress Physiology and Epigenetic Profiles in Brain. Toxicol Sci. 2018 Feb 21. PMID: 29481626.
      Citations:    
    13. Leehey M, Luo S, Sharma S, Wills AA, Bainbridge JL, Wong PS, Simon DK, Schneider J, Zhang Y, Pérez A, Dhall R, Christine CW, Singer C, Cambi F, Boyd JT. Association of metabolic syndrome and change in Unified Parkinson's Disease Rating Scale scores. Neurology. 2017 Oct 24; 89(17):1789-1794. PMID: 28972194.
      Citations:    
    14. Simon DK, Wu C, Tilley BC, Lohmann K, Klein C, Payami H, Wills AM, Aminoff MJ, Bainbridge J, Dewey R, Hauser RA, Schaake S, Schneider JS, Sharma S, Singer C, Tanner CM, Truong D, Wei P, Wong PS, Yang T. Caffeine, creatine, GRIN2A and Parkinson's disease progression. J Neurol Sci. 2017 Apr 15; 375:355-359. PMID: 28320167.
      Citations:    
    15. Wills AA, Elm JJ, Ye R, Chou KL, Parashos SA, Hauser RA, Bodis-Wollner I, Hinson VK, Christine CW, Schneider JS. Cognitive function in 1736 participants in NINDS Exploratory Trials in PD Long-term Study-1. Parkinsonism Relat Disord. 2016 Oct 8. PMID: 27743701.
      Citations:    
    16. Schneider JS, Anderson DW, Kidd SK, Sobolewski M, Cory-Slechta DA. Sex-dependent effects of lead and prenatal stress on post-translational histone modifications in frontal cortex and hippocampus in the early postnatal brain. Neurotoxicology. 2016 May; 54:65-71. PMID: 27018513.
      Citations:    
    17. Schneider JS, Seyfried TN, Choi HS, Kidd SK. Intraventricular Sialidase Administration Enhances GM1 Ganglioside Expression and Is Partially Neuroprotective in a Mouse Model of Parkinson's Disease. PLoS One. 2015; 10(12):e0143351. PMID: 26629687.
      Citations:    
    18. Simon DK, Wu C, Tilley BC, Wills AM, Aminoff MJ, Bainbridge J, Hauser RA, Schneider JS, Sharma S, Singer C, Tanner CM, Truong D, Wong PS. Caffeine and Progression of Parkinson Disease: A Deleterious Interaction With Creatine. Clin Neuropharmacol. 2015 Sep-Oct; 38(5):163-9. PMID: 26366971.
      Citations:    
    19. Schneider JS, Cambi F, Gollomp SM, Kuwabara H, Brašic JR, Leiby B, Sendek S, Wong DF. GM1 ganglioside in Parkinson's disease: Pilot study of effects on dopamine transporter binding. J Neurol Sci. 2015 Sep 15; 356(1-2):118-23. PMID: 26099170.
      Citations:    
    20. Schneider JS, Sendek S, Yang C. Relationship between Motor Symptoms, Cognition, and Demographic Characteristics in Treated Mild/Moderate Parkinson's Disease. PLoS One. 2015; 10(4):e0123231. PMID: 25905783.
      Citations:    
    21. Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial. JAMA. 2015 Feb 10; 313(6):584-93. PMID: 25668262.
      Citations:    
    22. Umeh CC, Pérez A, Augustine EF, Dhall R, Dewey RB, Mari Z, Simon DK, Wills AM, Christine CW, Schneider JS, Suchowersky O. No Sex Differences in Use of Dopaminergic Medication in Early Parkinson Disease in the US and Canada - Baseline Findings of a Multicenter Trial. PLoS One. 2014; 9(12):e112287. PMID: 25486269.
      Citations:    
    23. Schneider JS, Ault ME, Anderson DW. Retinal Pathology detected by optical coherence tomography in an animal model of Parkinson's disease. Mov Disord. 2014 Oct; 29(12):1547-51. PMID: 25070726.
      Citations:    
    24. Schneider JS, Talsania K, Mettil W, Anderson DW. Genetic diversity influences the response of the brain to developmental lead exposure. Toxicol Sci. 2014 Sep 1; 141(1):29-43. PMID: 24913800.
      Citations:    
    25. Halliday GM, Leverenz JB, Schneider JS, Adler CH. The neurobiological basis of cognitive impairment in Parkinson's disease. Mov Disord. 2014 Apr 15; 29(5):634-50. PMID: 24757112.
      Citations:    
    26. Verina T, Schneider JS, Guilarte TR. Manganese exposure induces a-synuclein aggregation in the frontal cortex of non-human primates. Toxicol Lett. 2013 Mar 13; 217(3):177-83. PMID: 23262390.
      Citations:    
    27. Schneider JS, Pioli EY, Jianzhong Y, Li Q, Bezard E. Levodopa improves motor deficits but can further disrupt cognition in a macaque parkinson model. Mov Disord. 2013 Apr 15; 28(5):663-7. PMID: 23238827.
      Citations:    
    28. Schneider JS, Gollomp SM, Sendek S, Colcher A, Cambi F, Du W. A randomized, controlled, delayed start trial of GM1 ganglioside in treated Parkinson's disease patients. J Neurol Sci. 2013 Jan 15; 324(1-2):140-8. PMID: 23199590.
      Citations:    
    29. Schneider JS, Pioli EY, Jianzhong Y, Li Q, Bezard E. Effects of memantine and galantamine on cognitive performance in aged rhesus macaques. Neurobiol Aging. 2013 Apr; 34(4):1126-32. PMID: 23158762.
      Citations:    
    30. Schneider JS, Anderson DW, Talsania K, Mettil W, Vadigepalli R. Effects of developmental lead exposure on the hippocampal transcriptome: influences of sex, developmental period, and lead exposure level. Toxicol Sci. 2012 Sep; 129(1):108-25. PMID: 22641619.
      Citations:    
    31. Zeamer A, Clark K, Bouquio C, Decamp E, Schneider JS. Impaired spatial working memory learning and performance in normal aged rhesus monkeys. Behav Brain Res. 2012 Jun 15; 232(1):287-93. PMID: 22546522.
      Citations:    
    32. Paule MG, Green L, Myerson J, Alvarado M, Bachevalier J, Schneider JS, Schantz SL. Behavioral toxicology of cognition: extrapolation from experimental animal models to humans: behavioral toxicology symposium overview. Neurotoxicol Teratol. 2012 Mar; 34(2):263-73. PMID: 22311110.
      Citations:    
    33. Decamp E, Clark K, Schneider JS. Effects of the alpha-2 adrenoceptor agonist guanfacine on attention and working memory in aged non-human primates. Eur J Neurosci. 2011 Sep; 34(6):1018-22. PMID: 21883531.
      Citations:    
    34. Anderson DW, Schray RC, Duester G, Schneider JS. Functional significance of aldehyde dehydrogenase ALDH1A1 to the nigrostriatal dopamine system. Brain Res. 2011 Aug 23; 1408:81-7. PMID: 21784415.
      Citations:    
    35. Verina T, Kiihl SF, Schneider JS, Guilarte TR. Manganese exposure induces microglia activation and dystrophy in the substantia nigra of non-human primates. Neurotoxicology. 2011 Mar; 32(2):215-26. PMID: 21112353.
      Citations:    
    36. Millan MJ, Buccafusco JJ, Loiseau F, Watson DJ, Decamp E, Fone KC, Thomasson-Perret N, Hill M, Mocaer E, Schneider JS. The dopamine D3 receptor antagonist, S33138, counters cognitive impairment in a range of rodent and primate procedures. Int J Neuropsychopharmacol. 2010 Sep; 13(8):1035-51. PMID: 20663270.
      Citations:    
    37. Kidd SK, Schneider JS. Protection of dopaminergic cells from MPP+-mediated toxicity by histone deacetylase inhibition. Brain Res. 2010 Oct 1; 1354:172-8. PMID: 20654591.
      Citations:    
    38. Schneider JS, Elm JJ, Parashos SA, Ravina BM, Galpern WR. Predictors of cognitive outcomes in early Parkinson disease patients: The National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) experience. Parkinsonism Relat Disord. 2010 Sep; 16(8):507-12. PMID: 20598621.
      Citations:    
    39. Cai J, Yang M, Poremsky E, Kidd S, Schneider JS, Iacovitti L. Dopaminergic neurons derived from human induced pluripotent stem cells survive and integrate into 6-OHDA-lesioned rats. Stem Cells Dev. 2010 Jul; 19(7):1017-23. PMID: 19824823.
      Citations:    
    40. Schneider JS, Sendek S, Daskalakis C, Cambi F. GM1 ganglioside in Parkinson's disease: Results of a five year open study. J Neurol Sci. 2010 May 15; 292(1-2):45-51. PMID: 20206941.
      Citations:    
    41. Yang C, Garrett-Mayer E, Schneider JS, Gollomp SM, Tilley BC. Repeatable battery for assessment of neuropsychological status in early Parkinson's disease. Mov Disord. 2009 Jul 30; 24(10):1453-60. PMID: 19452561.
      Citations:    
    42. Burton NC, Schneider JS, Syversen T, Guilarte TR. Effects of chronic manganese exposure on glutamatergic and GABAergic neurotransmitter markers in the nonhuman primate brain. Toxicol Sci. 2009 Sep; 111(1):131-9. PMID: 19520674.
      Citations:    
    43. Guilarte TR, Burton NC, McGlothan JL, Verina T, Zhou Y, Alexander M, Pham L, Griswold M, Wong DF, Syversen T, Schneider JS. Impairment of nigrostriatal dopamine neurotransmission by manganese is mediated by pre-synaptic mechanism(s): implications to manganese-induced parkinsonism. J Neurochem. 2008 Dec; 107(5):1236-47. PMID: 18808452.
      Citations:    
    44. Guilarte TR, Burton NC, Verina T, Prabhu VV, Becker KG, Syversen T, Schneider JS. Increased APLP1 expression and neurodegeneration in the frontal cortex of manganese-exposed non-human primates. J Neurochem. 2008 Jun; 105(5):1948-59. PMID: 18284614.
      Citations:    
    45. Kulak JM, Fan H, Schneider JS. Beta2* and beta4* nicotinic acetylcholine receptor expression changes with progressive parkinsonism in non-human primates. Neurobiol Dis. 2007 Sep; 27(3):312-9. PMID: 17616467.
      Citations:    
    46. Aschner M, Guilarte TR, Schneider JS, Zheng W. Manganese: recent advances in understanding its transport and neurotoxicity. Toxicol Appl Pharmacol. 2007 Jun 1; 221(2):131-47. PMID: 17466353.
      Citations:    
    47. Anderson DW, Bradbury KA, Schneider JS. Neuroprotection in Parkinson models varies with toxin administration protocol. Eur J Neurosci. 2006 Dec; 24(11):3174-82. PMID: 17156378.
      Citations:    
    48. Schneider JS, Decamp E, Koser AJ, Fritz S, Gonczi H, Syversen T, Guilarte TR. Effects of chronic manganese exposure on cognitive and motor functioning in non-human primates. Brain Res. 2006 Nov 6; 1118(1):222-31. PMID: 16978592.
      Citations:    
    49. Guilarte TR, McGlothan JL, Degaonkar M, Chen MK, Barker PB, Syversen T, Schneider JS. Evidence for cortical dysfunction and widespread manganese accumulation in the nonhuman primate brain following chronic manganese exposure: a 1H-MRS and MRI study. Toxicol Sci. 2006 Dec; 94(2):351-8. PMID: 16968886.
      Citations:    
    50. Guilarte TR, Chen MK, McGlothan JL, Verina T, Wong DF, Zhou Y, Alexander M, Rohde CA, Syversen T, Decamp E, Koser AJ, Fritz S, Gonczi H, Anderson DW, Schneider JS. Nigrostriatal dopamine system dysfunction and subtle motor deficits in manganese-exposed non-human primates. Exp Neurol. 2006 Dec; 202(2):381-90. PMID: 16925997.
      Citations:    
    51. Kulak JM, Carroll FI, Schneider JS. [125I]Iodomethyllycaconitine binds to alpha7 nicotinic acetylcholine receptors in monkey brain. Eur J Neurosci. 2006 May; 23(10):2604-10. PMID: 16817863.
      Citations:    
    52. Wade TV, Schneider JS. Striatal preprotachykinin gene expression reflects parkinsonian signs. Neuroreport. 2004 Nov 15; 15(16):2481-4. PMID: 15538179.
      Citations:    
    53. Kulak JM, Schneider JS. Differences in alpha7 nicotinic acetylcholine receptor binding in motor symptomatic and asymptomatic MPTP-treated monkeys. Brain Res. 2004 Mar 5; 999(2):193-202. PMID: 14759498.
      Citations:    
    54. Lidsky TI, Schneider JS. Lead neurotoxicity in children: basic mechanisms and clinical correlates. Brain. 2003 Jan; 126(Pt 1):5-19. PMID: 12477693.
      Citations:    
    55. Schneider JS, Wade TV. Experimental parkinsonism is associated with increased pallidal GAD gene expression and is reversed by site-directed antisense gene therapy. Mov Disord. 2003 Jan; 18(1):32-40. PMID: 12518298.
      Citations:    
    56. Schroeder JA, Schneider JS. GABA(A) and mu-opioid receptor binding in the globus pallidus and endopeduncular nucleus of animals symptomatic for and recovered from experimental Parkinsonism. Brain Res. 2002 Aug 30; 947(2):284-9. PMID: 12176171.
      Citations:    
    Schneider's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (214)
    Explore
    _
    Co-Authors (7)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _
    Physical Neighbors
    _